Shots:

• I-Mab to receive ~$35M up front & ~0.27M upon achievement of development, registration & sales milestones, $315M non-royalty payment & is eligible to receive royalties. The companies will share profits of the product in mainland China on a 50/50 basis
• The collaboration will combine I-Mab's leadership in drug innovation & manufacturing with Jumpcan's commercial leadership with its proven capabilities to develop & commercialize eftansomatropin alfa
• I-Mab will offer clinical, manufacturing & academic support & will be the MAH of the product that supplies to Jumpcan at an agreed cost. Jumpcan will be responsible for commercializing the product & developing new indications in mainland China

  Ref: PR Newswire | Image: I-Mab